Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 18, 2011

Shire, Shionogi Ink Co-Development Agreement for ADHD Drugs in Japan

  • Intent on tapping one of the world’s fastest-growing markets for ADHD treatments, Shire and Japan’s Shionogi & Co. agreed to co-develop and co-commercialize some of Shire’s medicines for the psychiatric behavioral disorder. Upon approval of medicines for Japan, Shionogi will pay a one-time fee and share costs with Shire.

     

    Shire’s drugs for ADHD include Adderall XR, Intuniv, Vyvanse. All three recorded double-digit year-over-year sales gains during the third quarter, with the first two increasing by 50%, and Vyvanse, by 32%. Shionogi develops medicines for the central nervous system, among other therapeutic areas.

     

    The agreement comes nearly three years after Shire opened a representative office in Japan, with the goal of stepping up commercialization of its pipeline products in Japan, the world’s second largest biopharmaceutical market.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »